Burden of illness associated with Respiratory Syncytial Virus (RSV)-related hospitalizations among adults in Ontario, Canada: A retrospective population-based study.

Autor: Mac S; Takeda Pharmaceutical, Toronto, Canada., Shi S; IQVIA, Montreal, Quebec, Canada., Millson B; IQVIA, Montreal, Quebec, Canada., Tehrani A; IQVIA, Montreal, Quebec, Canada., Eberg M; IQVIA, Montreal, Quebec, Canada., Myageri V; IQVIA, Montreal, Quebec, Canada., Langley JM; Canadian Center for Vaccinology (Dalhousie University, IWK Health and Nova Scotia Health) Halifax, Nova Scotia, Canada., Simpson S; Janssen Inc., Toronto, Ontario, Canada. Electronic address: ssimps14@its.jnj.com.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2023 Aug 07; Vol. 41 (35), pp. 5141-5149. Date of Electronic Publication: 2023 Jul 06.
DOI: 10.1016/j.vaccine.2023.06.071
Abstrakt: Background: Globally, RSV is a common viral pathogen that causes 64 million acute respiratory infections annually. Our objective was to determine the incidence of hospitalization, healthcare resource use and associated costs of adults hospitalized with RSV in Ontario, Canada.
Methods: To describe the epidemiology of adults hospitalized with RSV, we used a validated algorithm applied to a population-based healthcare utilization administrative dataset in Ontario, Canada. We created a retrospective cohort of incident hospitalized adults with RSV between September 2010 and August 2017 and followed each person for up to two years. To determine the burden of illness associated with hospitalization and post-discharge healthcare encounters each RSV-admitted patient was matched to two unexposed controls based on demographics and risk factors. Patient demographics were described and mean attributable 6-month and 2-year healthcare costs (2019 Canadian dollars) were estimated.
Results: There were 7,091 adults with RSV-associated hospitalizations between 2010 and 2019 with a mean age of 74.6 years; 60.4 % were female. RSV-coded hospitalization rates increased from 1.4 to 14.6 per 100,000 adults between 2010-2011 and 2018-2019. The mean difference in healthcare costs between RSV-admitted patients and matched controls was $28,260 (95 % CI: $27,728 - $28,793) in the first 6 months and $43,721 over 2 years (95 % CI: $40,383 - $47,059) post-hospitalization.
Conclusions: RSV hospitalizations among adults increased in Ontario between 2010/11 to 2018/19 RSV seasons. RSV hospitalizations in adults were associated with increased attributable short-term and long-term healthcare costs compared to matched controls. Interventions that could prevent RSV in adults may reduce healthcare burden.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Scott Simpson reports financial support was provided by Janssen Pharmaceuticals Inc. Joanne Langley reports a relationship with GSK Vaccines that includes: funding grants. Dr. Langley is employed by Dalhousie University, which receives funding for research studies from GSK, Janssen, and Merck.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: